MPL and autoimmune thrombocytopenic purpura: The three major second‐line therapies for ITP include the anti‐CD20 monoclonal antibody rituximab; the thrombopoietin receptor agonists (TRAs), romiplostim, eltrombopag, and avatrombopag; and splenectomy.1